新药研发新药研发新药研发聚焦于细胞治疗、基因治疗、抗体药物等创新药物的开发，致力于与临床医生共同将具有重大临床意义的科学研究进行临床转化，开发能够解决临床迫切需求的治疗产品。
目前已经建立起包含CAR-T、TCR-T等细胞治疗项目，AAV基因治疗项目以及单克隆抗体项目在内的完整的开发管线，并与多名领域带头人签署了长期的深度合作协议。
| Cell Therapy | Target Validation | Lead | Candidate | Clinical Study | ||
| CD19 GB5005 | Leukemia CAR-T |
|
|
|
|
Phase：Clinical Study |
| BCMA GB5010 | Multiple Melanoma CAR-T |
|
|
|
|
Phase：Clinical Study |
| GPC3 GB5011 | Liver Cancer CAR-T |
|
|
|
|
Phase：Clinical Study |
| CEACAM5 GB5012 | Colon Cancer CAR-T |
|
|
|
|
Phase：Clinical Study |
| MG7 GB70015 | Gastric Cancer (FIC) CAR-T |
|
|
|
|
Phase：Clinical Study |
| Claudin 18.2 GB70041 | Gastric Cancer CAR-T |
|
|
|
Phase：Candidate | |
| NY-ESO-1 GB3007 | Synovial Sarcoma TCR-T |
|
Phase：Target Validation | |||
| RASm GB3010 | Pancreatic Cancer (FIC) TCR-T |
|
Phase：Target Validation | |||
| EBV GB3015 | Nasopharyngeal Carcinoma TCR-T |
|
Phase：Target Validation | |||
| Therapeatic Antibody | Target Validation | Lead | Candidate | Clinical Study | ||
| Claudin 18.2 GB7004 | Gastric Cancer mAb |
|
|
|
|
Phase：Candidate |
| MG7 GB7001 | Gastric Cancer (FIC) mAb |
|
|
|
Phase：Candidate | |
| CD73 GB7002 | Solid Tumor mAb |
|
|
|
Phase：Candidate | |
| CEACAM5 GB7012 | Colon Cancer mAb |
|
|
|
Phase：Candidate | |
| PD-L1 GB7003 | Solid Tumor mAb |
|
|
|
Phase：Candidate | |
| CD47 GB7005 | Solid Tumor mAb |
|
|
|
Phase：Candidate | |
| NY-ESO-1 GB7007 | Sarcoma (FIC) mAb |
|
|
Phase：Lead | ||
| Claudin 6 GB7008 | Ovarian Cancer mAb |
|
|
Phase：Lead | ||
